Cargando…

466. All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Open-label Study (FURI)

BACKGROUND: There are limited oral antifungal treatment options for patients with high-mortality fungal infections such as candidemia or invasive candidiasis who fail available antifungals or have infection caused by resistant fungi. Ibrexafungerp is a broad-spectrum glucan synthase inhibitor with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prattes, Juergen, King, Thomas, Azie, Nkechi, Angulo, David A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752405/ http://dx.doi.org/10.1093/ofid/ofac492.524

Ejemplares similares

P057 All- cause mortality in patients with invasive Candidiasis or candidemia from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Thompson, George R, et al.
Publicado: (2022)

123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Pappas, Peter G, et al.
Publicado: (2021)

1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Alexander, Barbara D, et al.
Publicado: (2020)

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)

The sound and the fury /
por: Faulkner, William, 1897-1962
Publicado: (1959)

The sound and the fury /
por: Faulkner, William, 1897-1962
Publicado: (1964)

Clang and fury
por: Hillborg, Anders, 1954-
Publicado: (1992)

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
por: Nyirjesy, Paul, et al.
Publicado: (2021)

Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
por: Ruhnke, M, et al.
Publicado: (2011)

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
por: Goje, Oluwatosin, et al.
Publicado: (2023)

On the Fury Fits of the Elephant
Publicado: (1831)

The sound and the fury ; &, As I lay dying /
por: Faulkner, William, 1897-1962
Publicado: (1946)

Invasive candidiasis and candidemia in pediatric and neonatal patients: A review of current guidelines
por: Vasileiou, Eleni, et al.
Publicado: (2018)

Les éléments en furie
por: Pour la Science
Publicado: (2006)

Canada fury at WHO ban
por: Kondro, Wayne
Publicado: (2003)

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia
por: Gebretekle, Gebremedhin Beedemariam, et al.
Publicado: (2022)

Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial
por: Vazquez, Jose, et al.
Publicado: (2014)

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
por: Kett, Daniel H, et al.
Publicado: (2011)

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients
por: Grau, S, et al.
Publicado: (2015)

Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
por: van Prehn, Joffrey, et al.
Publicado: (2017)

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

Ocular Candidiasis in Patients with Candidemia at a Large Tertiary Care Center
por: Lee, Bonny, et al.
Publicado: (2017)

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
por: Roilides, Emmanuel, et al.
Publicado: (2020)

Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil
por: Vianna, Cid Manso de Mello, et al.
Publicado: (2023)

Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008
por: Pfaller, Michael A., et al.
Publicado: (2014)

Dark Matter Transcripts: Sound and Fury, Signifying Nothing?
por: Robinson, Richard
Publicado: (2010)

Love, fury, and old age: Escombros by Fernando Vallejo
por: Román Nieto, Luis Alfredo
Publicado: (2022)

Bowel hath no fury like a gallbladder inflamed
por: Khan, Amad, et al.
Publicado: (2014)

The Sound and the Fury—Bees Hiss when Expecting Danger
por: Wehmann, Henja-Niniane, et al.
Publicado: (2015)

Longitudinal Evaluation of Plasma Cytokine Levels in Patients with Invasive Candidiasis
por: Wunsch, Stefanie, et al.
Publicado: (2021)

Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia
por: Sakai, Daiki, et al.
Publicado: (2021)

1702. Disseminated Candidiasis after Candidemia: Epidemiology, Diagnostic Evaluation, and Risk Factors
por: Whitehurst, Daniel, et al.
Publicado: (2023)

1697. Comparison of Candidemia in Patients in Neonatal Intensive Care Unit and Pediatric Patients and Big Data Analysis on Candidiasis and Candidemia in Korean Children
por: Choi, Joon-sik, et al.
Publicado: (2019)

Tragedies, Fates, Furies and Fuels: Narratives of Individuals Bereaved by Suicide
por: Macdonald, Diane, et al.
Publicado: (2022)

369. Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis
por: Rao, Arni Sr Srinivasa, et al.
Publicado: (2018)

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
por: Thompson, George R, et al.
Publicado: (2020)

468. Assessment of The Proportion of Hospitalized Patients (Pts) with Candidemia (C) and Invasive Candidiasis without Candidemia (IC) Who Received an Echinocandin (EC) and Were Potentially Eligible for an Earlier Hospital Discharge (HD)
por: Lodise, Thomas, et al.
Publicado: (2022)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hc37unluloetbjoahqb647d4tq